MRUS News and Press, Merus N.V. From 10/08/21

While the S&P 500 index eked out a ~0.8% gain over the week, its healthcare constituents slipped ~0.3% to record the fifth consecutive weekly loss. Dragged down by biotech stocks, the sector became the second-worst performer in the index. Among healthcare stocks with more than $...

A day of gains on Wall Street helped investors forget some of their recent worries on Thursday. This applied to much-maligned (and much-sold) China-based tech stocks, as Alibaba (NYSE:BABA) led a rally in the sector. Baidu (NASDAQ:BIDU), DiDi (NYSE:DIDI) and NetEase (NASDAQ:NTES) also posted ...

4 Biotech Stocks To Add To Your October 2021 Watchlist In good times and bad, people and investors alike often turn to the health care industry. In particular, biotech stocks remain viable plays in the stock market today, nonetheless. For starters, investors appear to be breathi...

Gainers: Camber Energy (NYSE:CEI) +97%. Merus (NASDAQ:MRUS) +32%. New Fortress Energy (NASDAQ:NFE) +25%. Paltalk (NASDAQ:PALT) +25%. Grom Social Enterprises (NASDAQ:GROM) +20%. DatChat (NASDAQ:DATS) +20%. Jupiter Wellness (NASDAQ:JUPW) +18%. NextPlay Technologies (NASDAQ:NXTP) +19%. Independe...

Gainers: Merus (NASDAQ:MRUS) +36%, Nutriband (OTCQB:NTRB) +16%, Skylight Health (NASDAQ:SLHG) +16%, Rani Therapeutics (NASDAQ:RANI) +12%, Jupiter Wellness (NASDAQ:JUPW) +12%. Losers: Osmotica Pharmaceuticals (NASDAQ:OSMT) -38%, Prelude Therapeutics (NAS...

Shares of Merus (NASDAQ: MRUS) , a clinical-stage biopharmaceutical company, are soaring today in response to positive clinical trial results. Investors impressed with the company's latest presentation pushed the stock 39% higher as of 10:16 a.m. EDT on Thursday. Today, Merus pr...

Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with MCLA-158 In preclinical studies, Zeno observed to block cell growth 100 fold more potently than anti-HER3 antibody alone UTRECHT, The Netherlands a...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...

Merus (NASDAQ:MRUS): Q2 GAAP EPS of -$0.71 misses by $0.13. Revenue of $12.38M (+103.0% Y/Y) beats by $4.32M. Press Release For further details see: Merus EPS misses by $0.13, beats on revenue